BioStem Technologies, Inc. (BSEM)
| Market Cap | 242.70M |
| Revenue (ttm) | 301.83M |
| Net Income (ttm) | 31.88M |
| Shares Out | 16.70M |
| EPS (ttm) | 1.47 |
| PE Ratio | 9.88 |
| Forward PE | 2.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,911 |
| Average Volume | 87,424 |
| Open | 11.90 |
| Previous Close | 11.70 |
| Day's Range | 11.85 - 14.87 |
| 52-Week Range | 6.77 - 28.26 |
| Beta | 1.31 |
| RSI | 64.88 |
| Earnings Date | Apr 1, 2025 |
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical pr... [Read more]
Financial Performance
Financial StatementsNews
BioStem Technologies to Present at the Centri Capital Conference
POMPANO BEACH, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies, Inc. (BSEM) Q4 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q4 2024 Earnings Conference Call April 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Officer...
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or...
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
POMPANO BEACH, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies Announces Extension to File 2024 Annual Report with OTC
POMPANO BEACH, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of place...
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-...
BioStem Technologies: Building On Advanced Wound Care Needs
BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to ri...
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri...
Long-Term, BioStem Technologies Still A Promising Growth Stock
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive gro...
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Offi...
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri...
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies: A New Growth Star In Health Care
BioStem Technologies has enjoyed exceptional growth in its first year as a public company, with revenues soaring and earnings turning positive. The company's flagship product, AmnioWrap2, has been a m...
BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2024 Results Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executiv...
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...
Biostem Technologies, Inc. (BSEM) Q1 2024 Earnings Call Transcript
Biostem Technologies, Inc. (OTCPK:BSEM) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jeff Ramson - IR, PCG Advisory Group Jason Matuszewski - Chief Executive Officer M...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...